gms | German Medical Science

77. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

24.05. - 28.05.2006, Mannheim

Radioimmunotherapy of SCCHN in xenotransplantated SCID-Mice with a I-131-labeled Anti-EpCAM monoclonal antibody

Untersuchungen zur Radioimmuntherapie und Radioimmunszintigraphie bei Kopf-Hals-Tumoren mit einem radioaktiv-markierten Antikörper gegen EpCAM im SCID-Mausmodell

Meeting Abstract

  • corresponding author presenting/speaker Christian W. Luebbers - Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany
  • Franz Josef Gildehaus - Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany
  • Veronika Johannson - Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany
  • Baerbel Schmitt - Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany
  • Brigitte Mack - Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany
  • Gilbert Reisbach - GSF-National Research Center for Environment and Health, Munich, Germany
  • Stephan Lang - Department of Otorhinolaryngology, Head and Neck Surgery, University of Schleswig- Holstein, Luebeck, Germany
  • Olivier Gires - Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany
  • Reinhard Zeidler - Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany
  • Michaela Andratschke - Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany

German Society of Otorhinolaryngology, Head and Neck Surgery. 77th Annual Meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery. Mannheim, 24.-28.05.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06hno069

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2006/06hno069.shtml

Veröffentlicht: 7. September 2006

© 2006 Luebbers et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: The mortality of squamous cell carcinoma of the head and neck (SCCHN) still remains worse. Therefore new therapeutical strategies are necessary. One promising approach is the application of radio-labeled antibodies against tumour-associated antigens. EpCAM, showing a de novo-expression on SCCHN, is a suitable anchor molecule for such a Radioimmunotherapy (RIT). Aim of this study was to establish an in vivo-model with a radio-labelled monoclonal antibody (MAb) against this antigen.

Materials and Methods: The MAb C215 was labeled with 131I and tested for its capacity to eradicate established SCCHN xenografts growing subcutaneous in SCID mice. Initially, the biodistribution was determined by scarifying mice and dissecting organs at a given time after administration of the radio-labeled antibody and measuring the % injected dose/gram tissue in the gammacounter. For therapy, mice received a single bolus injection of 5, 15 or 25 MBq 131I-labeled MAb C215. Control animals received sodium chloride or the unlabeled MAb. Tumor growth and weight of the animals were determined at a particular time after administration of the antibody.

Results: Tumors in the groups receiving sodium chloride, unlabeled MAb C215 or 5 MBq of 131I-labeled MAb C215 showed exponential growth. Tumors in the groups receiving 15 MBq or 25 MBq of 131I-labeled MAb C215 showed delay of growth or regression. Since treatment related toxicity continued reaching median of 20 % weight loss mice were sacrificed at day 17 (25 MBq) and day 23 (15 MBq). At that time treatment control ratio of 12 % (15 MBq) and 29 % (25 MBq) could be determined.

Conclusion: Our data demonstrate that using radio-labeled MAb C215 seems to be a promising tool to improve the outcome of SCCHN. Further studies are necessary to reduce the toxicity of such a therapy.